How GPCR-targeting therapies are advancing the fight against inflammatory disease
Drug Target Review
JUNE 16, 2025
In this article, Stephan Schann, Chief Scientific Officer at Domain Therapeutics , explains why this class of drug target is so useful despite the challenges they present. Preclinical studies have demonstrated potent and selective modulation of the immune response, which plays a crucial role in various inflammatory conditions.
Let's personalize your content